Restructuring |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Restructuring and Related Activities [Abstract] | |
| Restructuring | Restructuring In March 2025, the Company implemented changes to focus its efforts on advancing the clinical development of imdusiran and AB-101. The decision was made to exit the Company’s corporate headquarters in Warminster, Pennsylvania, implement workforce reductions and discontinue in-house scientific research. The restructuring has resulted in a total workforce after reductions of 16 employees as of June 30, 2026. As of June 30, 2026, there was a $0.2 million accrual for medical benefits and lease-related operating expenses included in accounts payable and accrued liabilities.
|